BioCentury
ARTICLE | Finance

MPM goes intracellular

How Entrada’s tech drew MPM Capital into intracellular biologics

December 19, 2018 11:03 PM UTC

MPM Capital picked Entrada Therapeutics Inc. for its debut investment in intracellular biologics because Entrada’s technology solves the long-time challenge of delivering biologics into cells and shows early promise of broad tissue distribution, MPM Capital’s Todd Foley told BioCentury.

MPM and 5AM Ventures co-led Entrada’s $59 million series A round, which closed on Tuesday. Existing investors Roche Venture Fund and MRL Ventures Fund (MRLV) and new investor Agent Capital also participated...